Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson's disease and as of March 2010 is in Phase III clinical trials. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.
Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%). It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.
See also
- Aripiprazole
- Bifeprunox
- Pimavanserin
References
Further reading
- Hauser RA, Bronzova J, Sampaio C, et al. (2009). "Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease". European Neurology 62 (1): 40â€"8. doi:10.1159/000216839. PMID 19407454.Â
- Bronzova J, Sampaio C, Hauser RA, et al. (March 2010). "Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society 25 (6): NAâ€"NA. doi:10.1002/mds.22948. PMID 20198713.Â